*Corresponding author:Atsushi Imai, Department of Obstetrics and Gynecology, Institute of Endocrine-Related Cancer, Matsunami General Hospital, Kasamatsu, Gifu 501-6062, Japan
Received: April 11, 2018; Published: April 20, 2018
To view the Full Article Peer-reviewed Article PDF
Dyslipidemia is highly common in women, particularly after the menopause. Menopause, caused by ovarian dysfunctions, is be associated with an increase in total and low-density lipoprotein-cholesterol (LDL-C) and a decrease in high density lipoprotein-cholesterol (HDL-C). Pitavastatin (2 mg/day, orally), one of new generation statin, in addition to its strong LDL-C lowering effect, revealed a higher efficacy to increase HDL-C level and improved elevated triglyceride (TG) level in Japanese peri- and postmenopausal women. Pitavastatin may be an effective treatment option in (post-)menopausal women with dyslipidemia, in conjunction with suggested lifestyle modification.
Keywords: Pitavastatin; Dyslipidemia; Low-Density Lipoprotein-Cholestero;, High Density Lipoprotein-Cholesterol; Triglyceride